Skip to main content

Hydrochlorothiazide & Utilization

Basic Details
Status
Ongoing
Last Updated
Friday, September 25, 2026
Original Posting Date
Health Outcome(s)
utilization
Purpose
Drug Utilization
Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
No
Analytic Code Link(s) (1)
Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: An Interrupted Time Series Analysis
Result(s) (2)
Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: An Updated Interrupted Time Series Analysis Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: An Interrupted Time Series Analysis
Regulatory Link(s) (2)
Hydrochlorothiazide & Non-Melanoma Skin Cancer FDA Labeling Change: Hydrochlorothiazide and Non-Melanoma Skin Cancer
Related Publication(s) and/or Presentation(s) (1)
Publication: Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer Risk